BPGbio Appoints John Dvor As Executive Vice President Of Corporate Development To Drive Strategic Growth And Partnerships

BPGbio, Inc., a clinical-stage biopharmaceutical company leveraging AI and advanced biological insights to pioneer therapies in mitochondrial biology and protein homeostasis, has announced the appointment of John Dvor as Executive Vice President of Corporate Development. In this strategic leadership role, Dvor will be responsible for driving the company’s corporate growth initiatives, including commercialization strategies, capital formation, mergers and acquisitions (M&A), and joint ventures aimed at advancing BPGbio’s therapeutic pipeline and AI platform assets.

Dvor brings over 20 years of experience in biotechnology, venture capital, and global finance. He most recently served as Managing Director at Miraki Innovation, a $175 million life sciences venture fund spun out of Massachusetts General Hospital, where he launched and scaled multiple health technology ventures. He also co-founded Tufts Health Ventures, a $250 million corporate VC fund at Tufts Health Plan, and currently serves as Venture Partner at C10 Labs, an AI-first venture fund spun out of MIT. Throughout his career, he has been involved in several high-impact transactions, including Iora Health’s $2.1 billion acquisition, SSI Innovations’ $1.3 billion IPO, and the out-licensing of BOA Biomedical from Harvard University’s Wyss Institute.

His appointment comes at a critical juncture for BPGbio, as the company moves closer to commercializing its clinically advanced programs and expanding its AI-validated assets. Central to BPGbio’s innovation strategy is its NAi® Interrogative Biology® platform, which combines one of the world’s largest clinically annotated biobanks with causal AI technology operating on the Frontier supercomputer. This unique integration has led to the discovery of more than 250 novel drug targets across 15 AI-driven disease models, with approximately 50 of these targets experimentally validated in oncology, neurology, and rare diseases.

The company has made significant progress in its clinical programs, recently completing enrollment in its Phase 2b glioblastoma (GBM) trial and advancing preparations for a registrational study in Primary CoQ10 Deficiency (PCQD), a rare pediatric mitochondrial disorder. Beyond these, BPGbio maintains a robust preclinical pipeline focused on E2-based targeted protein degradation and collaborates with over 60 leading institutions, including Oxford University, Stanford University, the U.S. Department of Defense, and the Uniformed Services University of the Health Sciences. These collaborations and assets position BPGbio as one of the most resource-rich and strategically placed companies in the biopharmaceutical sector, ready to expand through partnerships and market growth.

Commenting on the appointment, Niven R. Narain, Ph.D., President and CEO of BPGbio, said, “John’s appointment comes at a pivotal time as BPGbio advances a scientifically differentiated, clinically validated, and commercially ready portfolio. His extensive experience in building, financing, and creating successful outcomes for health companies will be instrumental in unlocking the full potential of our NAi platform and clinical programs through global partnerships and strategic initiatives.”

Sharing his perspective, Dvor stated, “BPGbio’s biology-first approach to AI drug development, coupled with its late-stage clinical programs and causal discovery platform, makes it one of the most compelling opportunities in biopharma today. With the average cost of developing a new drug nearing $6 billion, BPGbio’s model provides a sustainable solution—improving efficiency, reducing risk, and offering biologically validated targets ready for translation. The company’s 77% target validation rate far exceeds industry standards, positioning it for meaningful impact on both patient outcomes and investor returns.”

He further added, “BPGbio is asset-rich, platform-strong, and strategically positioned for global value creation. I’m honored to join the team and help guide its next phase of expansion and commercialization.”

Dvor has previously held senior roles at miR Scientific, Pluri Biotech, and ReMed Life Sciences, and has advised several global family offices, including the Aga Khan Foundation, Millhouse Capital, and Helge Capital. A U.S. Marine Corps veteran, he served in the White House Military Office during the Clinton and Bush administrations, earning Presidential Service Badge #17996. He holds an A.B. degree from Harvard University.